Beaufort Securities Maintains a “Speculative Buy” Rating on Nuformix Plc (LON:NFX); 12 Bullish Analysts Covering Kohl's (KSS)

Nuformix Plc (LON:NFX) stock “Speculative Buy” was restate at Beaufort Securities in analysts report sent to investors on 1 February.

Among 28 analysts covering Kohl’s Corporation (NYSE:KSS), 12 have Buy rating, 2 Sell and 14 Hold. Therefore 43% are positive. Kohl’s Corporation had 95 analyst reports since August 6, 2015 according to SRatingsIntel. As per Wednesday, January 18, the company rating was downgraded by Credit Suisse. The company was maintained on Thursday, December 14 by Guggenheim. The stock of Kohl's Corporation (NYSE:KSS) earned “Buy” rating by Jefferies on Saturday, July 29. Telsey Advisory Group maintained the shares of KSS in report on Friday, May 13 with “Outperform” rating. The stock has “Buy” rating by Robert W. Baird on Tuesday, January 16. Gordon Haskett downgraded Kohl's Corporation (NYSE:KSS) on Thursday, August 10 to “Hold” rating. The firm has “Buy” rating given on Friday, August 12 by Jefferies. The company was maintained on Tuesday, August 8 by Deutsche Bank. J.P. Morgan upgraded Kohl's Corporation (NYSE:KSS) on Friday, January 12 to “Buy” rating. The stock of Kohl's Corporation (NYSE:KSS) has “Outperform” rating given on Monday, October 9 by Telsey Advisory Group. See Kohl's Corporation (NYSE:KSS) latest ratings:

31/01/2018 Broker: Guggenheim Rating: Buy New Target: $75.0 Maintain
23/01/2018 Broker: Susquehanna Rating: Hold New Target: $64.0 Maintain
19/01/2018 Broker: Jefferies Rating: Buy New Target: $100.0 Maintain
16/01/2018 Broker: Robert W. Baird Rating: Buy New Target: $70.0 Maintain
12/01/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Upgrade
12/01/2018 Broker: RBC Capital Markets Old Rating: Underperform New Rating: Sector Perform Upgrade
12/01/2018 Broker: J.P. Morgan Rating: Buy New Target: $72.0 Upgrade
10/01/2018 Broker: Piper Jaffray Rating: Hold New Target: $55.0 Maintain
09/01/2018 Broker: Jefferies Rating: Buy New Target: $66.0 Maintain
09/01/2018 Broker: Guggenheim Rating: Buy New Target: $60.0 Maintain

The stock decreased 1.68% or $1.11 during the last trading session, reaching $64.77. About 3.65M shares traded. Kohl's Corporation (NYSE:KSS) has risen 7.16% since February 1, 2017 and is uptrending. It has underperformed by 9.54% the S&P500.

Investors sentiment increased to 0.94 in Q3 2017. Its up 0.08, from 0.86 in 2017Q2. It improved, as 46 investors sold Kohl's Corporation shares while 169 reduced holdings. 73 funds opened positions while 129 raised stakes. 175.28 million shares or 0.56% less from 176.27 million shares in 2017Q2 were reported. Moreover, James Invest has 0.07% invested in Kohl's Corporation (NYSE:KSS). Dubuque Fincl Bank owns 0% invested in Kohl's Corporation (NYSE:KSS) for 60 shares. Utah Retirement invested in 31,094 shares or 0.03% of the stock. Kentucky Retirement Systems accumulated 10,468 shares. The Illinois-based Guggenheim Cap has invested 0.11% in Kohl's Corporation (NYSE:KSS). State Of Wisconsin Board has 0.02% invested in Kohl's Corporation (NYSE:KSS). Pzena Investment Management Limited Com accumulated 347,073 shares. First Fincl Corporation In owns 100 shares for 0% of their portfolio. Nordea Invest Mngmt invested in 8,846 shares. 11,077 were reported by Jane Street Grp Limited Liability Corp. Shell Asset Mngmt holds 54,186 shares or 0.06% of its portfolio. Citadel Advsr Ltd Co invested 0.06% in Kohl's Corporation (NYSE:KSS). Strategic Global Lc owns 9,680 shares or 0.17% of their US portfolio. Visionary Asset Mgmt owns 0.1% invested in Kohl's Corporation (NYSE:KSS) for 7,906 shares. Brown Advisory holds 0% or 7,991 shares in its portfolio.

Kohl's Corporation operates department stores in the United States. The company has market cap of $10.88 billion. It offers private label, exclusive, and national brand apparel, footwear, accessories, beauty, and home products to children, men, and women customers. It has a 17.09 P/E ratio. The firm also sells its products online through Website Kohls.com.

Since September 1, 2017, it had 0 buys, and 3 insider sales for $1.05 million activity. Shares for $314,160 were sold by Boothby Lee K.

The stock decreased 1.37% or GBX 0.05 during the last trading session, reaching GBX 3.6. About 744,024 shares traded or Infinity% up from the average. Nuformix plc (LON:NFX) has 0.00% since February 1, 2017 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment increased to 1.09 in 2017 Q3. Its up 0.01, from 1.08 in 2017Q2. It increased, as 38 investors sold Nuformix plc shares while 122 reduced holdings. 43 funds opened positions while 132 raised stakes. 195.89 million shares or 2.01% less from 199.90 million shares in 2017Q2 were reported. Nuveen Asset Mgmt Limited Liability Co owns 46,870 shares. Legal And General Grp Inc Public Limited reported 942,162 shares stake. State Of Alaska Department Of Revenue accumulated 0.04% or 24,260 shares. 2.39M were reported by Goldman Sachs Gru Incorporated. The New York-based Alliancebernstein Lp has invested 0.01% in Nuformix plc (LON:NFX). Teachers Retirement Of The State Of Kentucky reported 196,356 shares. Holt Ltd Liability Dba Holt Lp invested in 0.13% or 13,355 shares. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 51,036 shares. 153,279 are held by Winslow Asset Management. Public Sector Pension Investment Board reported 9,626 shares. Tiaa Cref Ltd Limited Liability Company holds 1.13M shares or 0.02% of its portfolio. Sterling Capital Mgmt Limited Liability Com reported 25,160 shares stake. Moreover, Victory Mgmt has 0% invested in Nuformix plc (LON:NFX) for 39,992 shares. Dekabank Deutsche Girozentrale invested 0.04% of its portfolio in Nuformix plc (LON:NFX). Price T Rowe Associate Md owns 370,677 shares or 0% of their US portfolio.

Analysts await Nuformix plc (LON:NFX) to report earnings on February, 20 after the close. They expect $0.61 earnings per share, up 24.49% or $0.12 from last year’s $0.49 per share. NFX’s profit will be $2.81 million for 1.48 P/E if the $0.61 EPS becomes a reality. After $0.52 actual earnings per share reported by Nuformix plc for the previous quarter, Wall Street now forecasts 17.31% EPS growth.

Nuformix Plc develops pharmaceutical products using its cocrystal technology in the United Kingdom. The company has market cap of 16.59 million GBP. The Company’s lead programs include NXP001, which is used for oncology supportive care; and NXP002 for use in the treatment of fibrosis. It has a 18 P/E ratio.